LIVE DATA  ·  HONG KONG AI ECOSYSTEM  ·  364 COMPANIES EVALUATED  ·  52 VERIFIED  ·  POWERED BY KURATION AI  ·  CONTINUOUSLY UPDATED  ·  AUTONOMOUS AGENTS  ·  LAST UPDATED 2H AGO  ·   LIVE DATA  ·  HONG KONG AI ECOSYSTEM  ·  364 COMPANIES EVALUATED  ·  52 VERIFIED  ·  POWERED BY KURATION AI  ·  CONTINUOUSLY UPDATED  ·  AUTONOMOUS AGENTS  ·  LAST UPDATED 2H AGO  ·  

Preview modeshowing a sample of companies and people. Sign in for full access to emails, LinkedIn profiles, and the complete index.

Sign in
Alex Zhavoronkov
CEOInSilico Medicine Hong Kong Limited

Alex Zhavoronkov

Founder, CEO and CBO at Insilico Medicine

About

My posts and articles here are strictly personal, not reflective of positions or policies of Insilico Medicine, which disclaims any responsibility for my individual statements. I am also 100% focused on extending healthy, productive life for everyone on the planet. By citizenship, I am Canadian and Latvian. Any kind of war is against my religion, and I can not support any kind of war, military action, or disturbance of peace. I believe that countries and people need to work together to fight diseases and make the world more sustainable. In 2014, I founded Insilico Medicine (www.insilico.com) a global clinical-stage generative AI drug discovery. Until 2019, it was an AI-first drug discovery company, with most of the team focused exclusively on developing and applying deep learning methods to drug discovery. Insilico is the original inventor of multiple drug discovery technologies with multiple granted and pending patents in biomarker development and generative chemistry and generative biology. In 2019 the company started working on its own therapeutic programs focusing predominantly on immunology, oncology, fibrosis, and CNS. It also made its industrial-strength target discovery platforms (PandaOmics) and generative chemistry (Chemistry42) platforms available for licensing and partnering. It raised over $500 million from expert healthcare, biotechnology, and technology investors, and entered 2 Phase II clinical trials with the novel target discovered using AI and novel molecule designed using AI. Since 2019, Insilico nominated 22 preclinical candidates, 10 reached clinical stage, 1 completed Phase 2a. I also founded, co-chair and personally sponsor the largest global non-profit conference on aging research and drug discovery - Aging Research and Drug Discovery (ARDD), www.AgingPharma.org. In 2024, the University of Copenhagen will host 11th annual ARDD - please register early as it usually sells out in advance. Life positioning statement: www.LongevityPledge.org Publication record: http://www.ncbi.nlm.nih.gov/pubmed/?term=zhavoronkov+a https://scholar.google.com/citations?user=8Icccp0AAAAJ&hl=en Forbes.com articles: https://www.forbes.com/sites/alexzhavoronkov/ My book is out in English, Japanese, Chinese, and Polish: "The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy", Palgrave Macmillan, NY, 2013 http://www.amazon.com/The-Ageless-Generation-Biomedicine-Transform/dp/0230342205/ Email: alex@insilico.com FB: /biogerontology Twitter: @biogerontology

Experience

Chief Executive Officer and Chief Business Officer
Insilico Medicine
2025 – presentBoston, Massachusetts, United States
Founder and CEO
Insilico Medicine
2014 – presentCambridge, Massachusetts, United States
Scientific Advisor
HautAI OU
2017 – present
Chief Longevity Officer
Deep Longevity
2020 – 2024
Founder and CEO
Deep Longevity
2020 – 2020

Education

Queen's University
Bachelor of Commerce (Honors) · Finance, Management of Information Systems
Lomonosov Moscow State University (MSU)
PhD · Physics
The Johns Hopkins University
Master of Science · Biotechnology
Queen's University
Bachelor of Science · Computer Science

Skills

Biomedical EngineeringBiotechnologyScienceDiagnosticsEUEastern EuropePharmaceuticalsLife SciencesBloggingRisk ManagementCredit RiskGenetics